ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.97−0.03 (-3.47%)
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
ALX Oncology total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
ALX Oncology's total debt was $9.71M at Jun 30, 2026. For fiscal 2025 it was $9.75M, down 1.6% from the year before. The highest annual figure on record is $9.90M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.75M | -1.6% |
| FY2024 | Dec 31, 2024 | $9.90M | +2.7% |
| FY2023 | Dec 31, 2023 | $9.64M | +2.7% |
| FY2022 | Dec 31, 2022 | $9.39M | +73.2% |
| FY2019 | Dec 31, 2019 | $5.42M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.71M | -3.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.51M | -14.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.75M | -1.6% |
| Q3 FY2025 | Sep 30, 2025 | $10.11M | +2.8% |
| Q2 FY2025 | Jun 30, 2025 | $10.04M | +2.8% |
| Q1 FY2025 | Mar 31, 2025 | $9.97M | +2.8% |
| Q4 FY2024 | Dec 31, 2024 | $9.90M | +2.7% |
| Q3 FY2024 | Sep 30, 2024 | $9.84M | +2.7% |
| Q2 FY2024 | Jun 30, 2024 | $9.77M | +2.7% |
| Q1 FY2024 | Mar 31, 2024 | $9.70M | +2.7% |
| Q4 FY2023 | Dec 31, 2023 | $9.64M | +2.7% |
| Q3 FY2023 | Sep 30, 2023 | $9.58M | +66.2% |
| Q2 FY2023 | Jun 30, 2023 | $9.51M | +68.6% |
| Q1 FY2023 | Mar 31, 2023 | $9.45M | +74.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.76M | – |
| Q2 FY2020 | Jun 30, 2020 | $5.64M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.42M | – |
See a number that looks wrong?